Sébastien Baechler

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. pmc Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy
    Sébastien Baechler
    Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland
    Med Phys 39:6118-28. 2012
  2. pmc Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab
    Sébastien Baechler
    Institute of Radiation Physics, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    J Nucl Med 51:1878-84. 2010
  3. doi request reprint Individual monitoring of internal exposure for nuclear medicine workers in Switzerland
    S Baechler
    Institute of Radiation Physics, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Radiat Prot Dosimetry 144:464-7. 2011
  4. pmc Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan
    Sébastien Baechler
    The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Cancer Biother Radiopharm 23:633-9. 2008
  5. pmc Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry
    Sébastien Baechler
    Russell H Morgan Department of Radiology and Radiological Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 35:1123-34. 2008
  6. pmc Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore Maryland 21231, USA
    J Nucl Med 51:368-75. 2010
  7. pmc A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 80:1256-62. 2011
  8. doi request reprint Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide
    Ariane Boubaker
    Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Switzerland
    Eur J Nucl Med Mol Imaging 39:1868-75. 2012
  9. pmc A gamma camera count rate saturation correction method for whole-body planar imaging
    Robert F Hobbs
    Johns Hopkins University, Baltimore MD, USA
    Phys Med Biol 55:817-31. 2010
  10. ncbi request reprint Usefulness of specific calibration coefficients for gamma-emitting sources measured by radionuclide calibrators in nuclear medicine
    François O Bochud
    Institute of Radiation Physics, University Hospital and University of Lausanne, Rue du Grand Prd 1, CH 1007 Lausanne, Switzerland
    Med Phys 38:4073-80. 2011

Detail Information

Publications11

  1. pmc Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy
    Sébastien Baechler
    Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland
    Med Phys 39:6118-28. 2012
    ....
  2. pmc Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab
    Sébastien Baechler
    Institute of Radiation Physics, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    J Nucl Med 51:1878-84. 2010
    ..This study aimed at identifying clinical factors for predicting hematologic toxicity after radioimmunotherapy with (90)Y-ibritumomab tiuxetan or (131)I-tositumomab in clinical practice...
  3. doi request reprint Individual monitoring of internal exposure for nuclear medicine workers in Switzerland
    S Baechler
    Institute of Radiation Physics, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Radiat Prot Dosimetry 144:464-7. 2011
    ..In Switzerland, screening procedures have been adopted by most nuclear medicine services since such measurements enable an acceptable monitoring while taking into account practical and economic considerations...
  4. pmc Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan
    Sébastien Baechler
    The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Cancer Biother Radiopharm 23:633-9. 2008
    ....
  5. pmc Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry
    Sébastien Baechler
    Russell H Morgan Department of Radiology and Radiological Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 35:1123-34. 2008
    ..The MIRD-based BED formalism is expected to be useful for patient-specific adjustments of activity and to facilitate the investigation of dose-toxicity correlations with respect to dose-rate and tissue repair mechanism...
  6. pmc Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore Maryland 21231, USA
    J Nucl Med 51:368-75. 2010
    ..Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with (131)I-tositumomab...
  7. pmc A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 80:1256-62. 2011
    ..We have developed and tested a treatment planning method, using the patient-specific three-dimensional dosimetry package 3D-RD, for sequentially combined RPT/XRT therapy designed to limit toxicity to organs at risk...
  8. doi request reprint Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide
    Ariane Boubaker
    Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Switzerland
    Eur J Nucl Med Mol Imaging 39:1868-75. 2012
    ..The biokinetics and dosimetry of (111)In-DOTA-NOC-ATE (NOCATE), a high-affinity ligand of SSTR-2 and SSTR-5, and (111)In-DTPA-octreotide (Octreoscan™, OCTREO) were compared in the same patients...
  9. pmc A gamma camera count rate saturation correction method for whole-body planar imaging
    Robert F Hobbs
    Johns Hopkins University, Baltimore MD, USA
    Phys Med Biol 55:817-31. 2010
    ..e. time-dependent dead-time effects. The algorithm presented here accomplishes this task...
  10. ncbi request reprint Usefulness of specific calibration coefficients for gamma-emitting sources measured by radionuclide calibrators in nuclear medicine
    François O Bochud
    Institute of Radiation Physics, University Hospital and University of Lausanne, Rue du Grand Prd 1, CH 1007 Lausanne, Switzerland
    Med Phys 38:4073-80. 2011
    ..In nuclear medicine, the activity of a radionuclide is measured with a radionuclide calibrator that often has a calibration coefficient independent of the container type and filling...
  11. pmc A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 38:2892-903. 2011
    ..The authors present here an adaptation of the simple sphere-based model from which cellular level dosimetry for macroscopic tumors and their end point quantities, such as TCP, may be extrapolated more reliably...